These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661 [TBL] [Abstract][Full Text] [Related]
28. Antiplatelet drugs in the management of patients with thrombotic disorders. Harker LA Semin Thromb Hemost; 1986 Apr; 12(2):134-55. PubMed ID: 3016905 [No Abstract] [Full Text] [Related]
29. Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease. Rowe GG; Folts JD Clin Cardiol; 1990 Mar; 13(3):165-70. PubMed ID: 2182246 [TBL] [Abstract][Full Text] [Related]
30. Status of antiplatelet drugs in coronary heart disease. Mehta J; Mehta P JAMA; 1979 Jun; 241(24):2649-51. PubMed ID: 439365 [No Abstract] [Full Text] [Related]
31. Critical evaluation of platelet-inhibiting drugs in thrombotic disease. Harker LA; Hirsh J; Gent M; Genton E Prog Hematol; 1975; 9():229-54. PubMed ID: 766074 [No Abstract] [Full Text] [Related]
32. [Aspirin resistance: position paper of the working group on aspirin resistance of the international society on thrombosis and haemostasis]. Boskholov BP Kardiologiia; 2005; 45(7):75-6. PubMed ID: 16091668 [No Abstract] [Full Text] [Related]
33. Platelet-active drugs in the secondary prevention of cardiovascular events: an overview. Weiss HJ Circulation; 1980 Dec; 62(6 Pt 2):V41-3. PubMed ID: 7002351 [TBL] [Abstract][Full Text] [Related]
34. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Mazur P; Frołow M; Niżankowski R; Sadowski J; Undas A Platelets; 2013; 24(2):151-5. PubMed ID: 22497730 [TBL] [Abstract][Full Text] [Related]
35. [Effects of the beta-blocking agent atenolol on arrhythmias especially ventricular fibrillation and fibrillation threshold after acute experimental coronary artery occlusion (author's transl)]. Abendroth RR; Meesmann W; Stephan K; Schley G; Hübner H Z Kardiol; 1977 Jul; 66(7):341-50. PubMed ID: 899134 [No Abstract] [Full Text] [Related]
36. Comparative effects of verapamil and nifedipine on reactive hyperemia and ventricular arrhythmias during coronary artery reperfusion. Ribeiro LG; DeBauche TL; Brandon TA; Maroko PR; Miller RR Eur Heart J; 1980 Dec; 1(Suppl B):31-5. PubMed ID: 7348214 [No Abstract] [Full Text] [Related]
37. Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin. Josa M; Lie JT; Bianco RL; Kaye MP Am J Cardiol; 1981 Jun; 47(6):1248-54. PubMed ID: 6972158 [TBL] [Abstract][Full Text] [Related]
38. Comparison of a thromboxane receptor antagonist and aspirin in experimental arterial thrombosis. Schumacher WA; Heran CL; Youssef S; Megill JR; Michel I; Durham SK Haemostasis; 1993; 23(4):219-28. PubMed ID: 8314172 [TBL] [Abstract][Full Text] [Related]
39. The efficacy of antiarrhythmic agents during acute myocardial ischemia and the role of heart rate. Hope RR; Williams DO; el-Sherif N; Lazzara R; Scherlag BJ Circulation; 1974 Sep; 50(3):507-14. PubMed ID: 4416250 [No Abstract] [Full Text] [Related]